Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds100% diabetic wound closure in ≤ 12 weeksPreclinical sustained antibiofilm activity for a minimum of 7 days WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance of its FDA-cleared revyve® Antimicrobial Wound Gel and revyve Wound Gel Spray in both diabetic foot ulcer healing and burn wound infection contr ...

THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- TWFG, Inc. (NASDAQ: TWFG), a leading independent insurance distribution platform, announced today that it has acquired Alabama Insurance Agency, Inc., and its 20 affiliated locations across the state. This strategic acquisition strengthens TWFG’s presence in the Southeastern United States and reinforces its commitment to delivering personalized insurance solutions through a growing network of independent agents. Alabama Insurance Agency, known for its ...

交易概述 - Royalty Pharma以3.1亿美元收购Blackstone Life Sciences持有的AMVUTTRA特许权权益 [1] - 所收购的特许权权益源于Blackstone于2020年与Alnylam达成的融资合作，该合作旨在支持AMVUTTRA的关键性3期HELIOS-B试验 [1] 产品信息 - AMVUTTRA是一种经FDA批准的RNAi疗法，用于治疗ATTR淀粉样变性，这是一种由错误折叠蛋白在神经、心脏和胃肠道积聚引起的进行性、退行性且致命的疾病 [2] - AMVUTTRA于2025年获得FDA批准用于治疗伴有心肌病的TTR淀粉样变性，并于2022年获批用于治疗伴有多发性神经病的遗传性TTR淀粉样变性 [3] - 全球约有30,000名遗传性TTR淀粉样变性伴多发性神经病患者，以及超过300,000名ATTR心肌病患者，其中仅20%目前得到诊断 [3] 市场表现与前景 - AMVUTTRA在2024年销售额达到约10亿美元，同比增长74% [3] - 根据分析师共识，预计AMVUTTRA销售额到2028年将超过60亿美元 [3] - 伴有心肌病的TTR淀粉样变性是一个快速增长的治疗领域，驱动力来自新的治疗选择和不断提高的诊断率 [3] 交易条款细节 - Royalty Pharma收购了Blackstone持有的AMVUTTRA全球净销售额1%的特许权权益，支付3.1亿美元首付款 [4] - 该特许权权益的有效期将持续至2035年3月 [4] - 此次交易涉及AMVUTTRA自2025年10月1日起的销售额，并排除了作为原始交易一部分支付给Blackstone的固定付款 [4] - 在Blackstone的原始交易中，其投资额为7000万美元 [4] 公司背景 - Royalty Pharma成立于1996年，是生物制药特许权最大的收购方，也是生物制药行业创新的主要资助者 [6] - Royalty Pharma目前的投资组合包含超过35种商业化产品的特许权，以及17种在研产品候选物 [6] - Blackstone Life Sciences是行业领先的私募投资平台，目前管理着120亿美元资产 [7]

MONACO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Costamare Inc. (“Costamare” or the “Company”) (NYSE: CMRE) today reported unaudited financial results for the third quarter and nine-month period ended September 30, 2025. Discontinued operations as a result of Costamare Bulkers Holdings Limited Spin-Off The financial results for the nine-month period ended September 30, 2025, reflect the spin-off of Costamare’s dry bulk business (consisting of Costamare’s dry bulk owned fleet and its dry bulk operating platform, Co ...

Company expands partnership for employing a strategic focus on Bitcoin-native fintech, treasury services, and digital asset infrastructureLAS VEGAS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bitcoin Bancorp. (OTC: BCBC) (“Bitcoin Bancorp” or the “Company”), a leading advisor in Bitcoin treasury strategies and institutional digital asset management, today announced a groundbreaking platform in partnership with Sailo Technologies to unveil a comprehensive Bitcoin treasury management system. This innovative crypto tre ...

Revenues increased 92% to $252 million YoYNet income increased to $123 million from ($125) million in Q3 2024Bitcoin holdings increased 98% YoY to 52,850 from 26,747 at the end of Q3 2024 Miami, FL, Nov. 04, 2025 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA) ("MARA" or the "Company"), a leading digital energy and infrastructure company, today announced its third quarter 2025 financial results in a letter to shareholders. Investors are invited to access the third quarter 2025 shareholder letter at M ...

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pricing of its underwritten offering of 40,142,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,315,000 shares of common stock. The shares of common stock are being sold a ...

Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma basis versus Q3 2024 Continued cash management improvement, with cash used in operations of $0.8 million in Q3 2025 Strengthened balance sheet in Q3 2025, ending the quarter with $34.5 million of total cash, consisting of cash, cash equivalents, and restricted cash MALVERN, Pa., Nov. 04 ...

Q3 revenue increased 28% year-over-year to a record $181 million, driven by robust marketplace growth.Q3 marketplace revenue growth accelerated to 31% year-over-year, driven by strong enterprise growth and expanded networks of buyers and suppliers.Q3 gross profit increased 29% year-over-year to a record $72.0 million, driven by record marketplace gross margin of 35.7%.Q3 Adjusted EBITDA improved $6.8 million year-over-year to Adjusted EBITDA of $6.1 million driven by expanding marketplace gross margin and s ...

Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially into the third ...